Madrigal Pharmaceuticals (MDGL) to Release Quarterly Earnings on Wednesday

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($3.64) per share and revenue of $158.94 million for the quarter.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, beating the consensus estimate of ($3.62) by $0.30. The company had revenue of $137.25 million during the quarter, compared to analysts' expectations of $112.79 million. Madrigal Pharmaceuticals had a negative return on equity of 50.54% and a negative net margin of 123.38%. During the same period in the prior year, the business posted ($7.38) EPS. On average, analysts expect Madrigal Pharmaceuticals to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Madrigal Pharmaceuticals Trading Down 0.1%

MDGL traded down $0.34 during midday trading on Friday, reaching $302.17. 236,785 shares of the company's stock traded hands, compared to its average volume of 370,383. The firm has a fifty day moving average of $294.56 and a two-hundred day moving average of $311.29. The stock has a market capitalization of $6.71 billion, a price-to-earnings ratio of -16.74 and a beta of -1.05. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.91 and a quick ratio of 5.58. Madrigal Pharmaceuticals has a 52 week low of $200.63 and a 52 week high of $377.46.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MDGL shares. UBS Group upped their price target on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen raised Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. Canaccord Genuity Group increased their target price on Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. JMP Securities reissued a "market outperform" rating and issued a $443.00 target price on shares of Madrigal Pharmaceuticals in a research report on Thursday, April 24th. Finally, B. Riley reissued a "buy" rating and issued a $460.00 target price (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $420.63.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, Director Paul A. Friedman sold 26,176 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $353.47, for a total value of $9,252,430.72. Following the completion of the sale, the director owned 187,164 shares of the company's stock, valued at $66,156,859.08. The trade was a 12.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rebecca Taub sold 26,444 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $353.47, for a total value of $9,347,160.68. Following the completion of the transaction, the director directly owned 461,044 shares of the company's stock, valued at approximately $162,965,222.68. This trade represents a 5.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 60,377 shares of company stock worth $21,316,969 over the last three months. Insiders own 21.50% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.